Infections with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
- 1 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 70 (3), 313-333
- https://doi.org/10.2165/11533040-000000000-00000
Abstract
Since 2000, Escherichia coli producing CTX-M enzymes (especially CTX-M-15) have emerged worldwide as important causes of community-onset urinary tract infections (UTIs) and bloodstream infections due to extended-spectrum β-lactamase (ESBL)-producing bacteria. Molecular epidemiology studies suggested that the sudden worldwide increase of CTX-M-15-producing E. coli is mostly due to a single clone named ST131 and that foreign travel to high-risk areas such as the Indian subcontinent might in part play a role in the spread of this clone across different continents. Empirical antibacterial coverage for these resistant organisms should be considered in community patients presenting with sepsis involving the urinary tract especially if a patient recently travelled to a high-risk area. Infections due to ESBL-producing Enterobacteriaceae are associated with a delay in initiation of appropriate antibacterial therapy, which consequently prolongs hospital stays and increases hospital costs. Failure to initiate appropriate antibacterial therapy from the start appears to be responsible for higher patient mortality. The carbapenems are widely regarded as the drugs of choice for the treatment of severe infections due to ESBL-producing Enterobacteriaceae, although comparative clinical trials are lacking. Agents that may be useful for the treatment of ESBL-associated UTIs include fosfomycin, nitrofurantoin and temocillin. If this emerging public health threat is ignored, it is possible that clinicians may be forced in the near future to use the carbapenems as the first choice for empirical treatment of serious infections associated with UTIs originating from the community.Keywords
This publication has 120 references indexed in Scilit:
- Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007Antimicrobial Agents and Chemotherapy, 2009
- Molecular characterization of CTX‐M‐15‐producing clinical isolates of Escherichia coli reveals the spread of multidrug‐resistant ST131 (O25:H4) and ST964 (O102:H6) strains in NorwayAPMIS, 2009
- Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strainsJournal of Antimicrobial Chemotherapy, 2009
- Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15Journal of Antimicrobial Chemotherapy, 2009
- Dominance of bla CTX-M within an Australian Extended-Spectrum β-Lactamase Gene PoolAntimicrobial Agents and Chemotherapy, 2008
- Replicon typing of plasmids in Escherichia coli producing extended-spectrum β-lactamasesJournal of Antimicrobial Chemotherapy, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15Journal of Antimicrobial Chemotherapy, 2008
- Antibiotic Coresistance in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of TigecyclineAntimicrobial Agents and Chemotherapy, 2006
- Clonal Dissemination of a CTX-M-15 β-Lactamase-Producing Escherichia coli Strain in the Paris Area, Tunis, and BanguiAntimicrobial Agents and Chemotherapy, 2006